HCPCS Level IIdrugActive
J9347
Inj, tremelimumab-actl, 1 mg
BETOS: O1D
Effective: 2023-07-01
Description
Injection, tremelimumab-actl, 1 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Imjudo
Manufacturer
AstraZeneca Pharmaceuticals LP
HCPCS Dosage
1 MG
Billing Units
25.0000
2
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.